𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Predictive value of ALT and HBV DNA levels in response to sequential combination treatment of lamivudine and interferon in HBeAg—/ANTI-Hbe+ chronic hepatitis B

✍ Scribed by Kubilay Cinar; Mustafa Sarioglu; Hulya Cetinkaya; Mithat Bozdayi; Ozden Uzunalimoglu; Cihan Yurdaydin; Hakan Bozkaya

Book ID
118565283
Publisher
Elsevier Science
Year
2002
Tongue
English
Weight
113 KB
Volume
36
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prediction of the response to peg-interf
Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment
✍ Bettina E. Hansen; Erik H.C.J. Buster; Ewout W. Steyerberg; Emmanuel Lesaffre; H 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

## Abstract Peginterferon (PEG‐IFN) results in HBeAg loss combined with virologic response in only a minority of patients with HBeAg positive chronic hepatitis B. Baseline predictors of response to PEG‐IFN include HBV‐genotype, pre‐treatment HBV DNA levels, and ALT. The aims of this study were to d

Early on-treatment prediction of respons
Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels
✍ Vincent Rijckborst; Bettina E. Hansen; Yilmaz Cakaloglu; Peter Ferenci; Fehmi Ta 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB 👁 2 views

Ferenci is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche. Dr. Janssen is a consultant for and received grants from Roche, Bristol-Myers Squibb, Schering-Plough, Novartis, and Gilead. Dr. Flisiak received grants from Roche.